October 23, 2013
SIU med school part of national emphysema study
Individuals who are diagnosed with late-stage emphysema are needed to participate in a national multi-site study at Southern Illinois University School of Medicine in Springfield. The study is evaluating the Zephyr® endobronchial valve, an investigational, minimally invasive treatment option for individuals diagnosed with severe emphysema.
“This study could lead to a less invasive treatment for emphysema, resulting in improved patient breathing and quality of life,” said Dr. Stephen Hazelrigg, professor and chief of cardiothoracic surgery at SIU, who is directing the study.
The endobronchial valve is designed to decrease the diseased portion of the lungs and improve the ability of the healthier portion. This is expected to relieve the individual’s symptoms, allowing them to increase their activity levels and improve overall health.
Emphysema is a form of chronic obstructive pulmonary disease (COPD), which is a major cause of disability and a major public health problem. The World Health Organization ranks it as the fourth leading cause of death today and it is expected to become the third leading cause of death worldwide by the 2030s. Most patients suffering from emphysema currently have few options for treatment.
Volunteers must be between the ages of 40 and 75 years and have not smoked for four months prior to the screening interview. Each participant will receive a physical examination and other tests prior to the clinical trial starting date and during 10 follow-up visits over a five-year period. There is no charge to the participants for the tests and medications related to the study, which is sponsored by Pulmonx Inc.
If you are interested in participating in the study, contact Theresa Boley in SIU’s Cardiothoracic Surgery Division at email@example.com or call 217-545-5000 weekdays for a no cost consultation.